Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Low-dose KETamine as an Adjunct to MOrphine for Acute Pain in the ED: a Randomized, Double-blinded Clinical Trial

To see complete record on, please visit this link

Id: NCT05422001

Organisation Name: University of Aarhus

Overal Status: Recruiting

Start Date: May 31, 2022

Last Update: June 16, 2022

Lead Sponsor: University of Aarhus

Brief Summary: The KetMo study is an investigator-initiated, randomized, parallel group, double blinded trial investigating if ketamine as an adjunct to morphine improves pain treatment in the ED.

Patients in pain (assessed on NRS, 5 or more) will be randomized to low-dose ketamine or placebo as an adjunct to morphine. Patients with or without prior use of opioids will be randomized separately.

The primary outcome will be pain reduction, assessed on NRS, after 10 minutes. Secondary outcomes include pain reduction until 120 minutes after injection of study medicine, need for rescue opioid, side effects and patient- and provider satisfaction.

  • Acute Pain
  • Opioid Use

Total execution time in seconds: 0.20912909507751